The prognostic impact of inflammatory factors in patients with multiple myeloma treated with thalidomide in Korea
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Cheolsu | - |
dc.contributor.author | Lee, Ho Sup | - |
dc.contributor.author | Min, Chang-Ki | - |
dc.contributor.author | Lee, Je Jung | - |
dc.contributor.author | Kim, Kihyun | - |
dc.contributor.author | Yoon, Dok Hyun | - |
dc.contributor.author | Eom, Hyeon Seok | - |
dc.contributor.author | Lee, Hyewon | - |
dc.contributor.author | Lee, Won Sik | - |
dc.contributor.author | Shin, Ho-Jin | - |
dc.contributor.author | Lee, Ji Hyun | - |
dc.contributor.author | Park, Yong | - |
dc.contributor.author | Jo, Jae-Cheol | - |
dc.contributor.author | Do, Young Rok | - |
dc.contributor.author | Mun, Yeung-Chul | - |
dc.date.accessioned | 2021-09-04T13:04:58Z | - |
dc.date.available | 2021-09-04T13:04:58Z | - |
dc.date.created | 2021-06-18 | - |
dc.date.issued | 2015-09 | - |
dc.identifier.issn | 1226-3303 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/92610 | - |
dc.description.abstract | Background/Aims: The purpose of this study was to determine the correlations between inflammatory factors-including absolute lymphocyte count, lactate dehydrogenase, a2-microglobulin, albumin, C-reactive protein, and ferritin-and the prognosis for survival in patients with multiple myeloma (MM) treated with induction chemotherapy containing thalidomide and who underwent autologous stem cell transplantation (ASCT). Methods: Data from patients at 13 university hospitals in South Korea were collected retrospectively between December 2005 and May 2013. Results: The median age of the 232 patients was 57 years (range, 33 to 77) and the male to female ratio was 1.09: 1. In the multivariate analysis, fewer than two combined abnormal inflammatory factors was the only independent prognostic factor for superior progression-free survival (relative risk [RR], 0.618; 95% confidence interval [CI], 0.409 to 0.933; p = 0.022), and platelet count > 100 x 10(9)/L and fewer than two combined abnormal inflammatory factors were independent prognostic factors for superior overall survival (RR, 4.739; 95% CI, 1.897 to 11.839; p = 0.001 and RR, 0.263; 95% CI, 0.113 to 0.612; p = 0.002, respectively). Conclusions: Patients with two or more than two combined inflammatory factors who were treated with thalidomide induction chemotherapy and who underwent ASCT showed significantly shorter survival compared to those with fewer than two combined inflammatory factors. These results could be helpful for predicting prognosis in patients with MM. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | KOREAN ASSOC INTERNAL MEDICINE | - |
dc.subject | STEM-CELL TRANSPLANTATION | - |
dc.subject | NEWLY-DIAGNOSED PATIENTS | - |
dc.subject | STAGING SYSTEM | - |
dc.subject | DISEASE SEVERITY | - |
dc.subject | SERUM LEVELS | - |
dc.subject | THERAPY | - |
dc.subject | CANDIDATES | - |
dc.subject | MANAGEMENT | - |
dc.subject | SURVIVAL | - |
dc.subject | NETWORK | - |
dc.title | The prognostic impact of inflammatory factors in patients with multiple myeloma treated with thalidomide in Korea | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Park, Yong | - |
dc.identifier.doi | 10.3904/kjim.2015.30.5.675 | - |
dc.identifier.scopusid | 2-s2.0-84942092210 | - |
dc.identifier.wosid | 000366665900014 | - |
dc.identifier.bibliographicCitation | KOREAN JOURNAL OF INTERNAL MEDICINE, v.30, no.5, pp.675 - 683 | - |
dc.relation.isPartOf | KOREAN JOURNAL OF INTERNAL MEDICINE | - |
dc.citation.title | KOREAN JOURNAL OF INTERNAL MEDICINE | - |
dc.citation.volume | 30 | - |
dc.citation.number | 5 | - |
dc.citation.startPage | 675 | - |
dc.citation.endPage | 683 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.identifier.kciid | ART002028945 | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | General & Internal Medicine | - |
dc.relation.journalWebOfScienceCategory | Medicine, General & Internal | - |
dc.subject.keywordPlus | STEM-CELL TRANSPLANTATION | - |
dc.subject.keywordPlus | NEWLY-DIAGNOSED PATIENTS | - |
dc.subject.keywordPlus | STAGING SYSTEM | - |
dc.subject.keywordPlus | DISEASE SEVERITY | - |
dc.subject.keywordPlus | SERUM LEVELS | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordPlus | CANDIDATES | - |
dc.subject.keywordPlus | MANAGEMENT | - |
dc.subject.keywordPlus | SURVIVAL | - |
dc.subject.keywordPlus | NETWORK | - |
dc.subject.keywordAuthor | Multiple myeloma | - |
dc.subject.keywordAuthor | Thalidomide | - |
dc.subject.keywordAuthor | Prognosis | - |
dc.subject.keywordAuthor | Inflammation | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.